Lilly Builds Neuroscience into a New Long-Term Growth Driver
Eli Lilly's neuroscience business, currently representing only 2% of revenues, is experiencing strong 32% growth with key products Kisunla and Emgality. The company is aggressively expanding its neuroscience pipeline through acquisitions including AtaiBeckley for treatment-resistant depression therapies, positioning neuroscience as a potential long-term growth driver to diversify beyond its dominant cardiometabolic business.